Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia28 April 2014Corporate and M&A Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryExternal investment trend continues as offshore leader seals private equity deal‘Anything that begins with admin is at risk’ – the pressures fuelling firms’ business services cutsTrading places: Skadden creates new C-suite role as Davis Polk makes trophy sports signing‘For us, it all came together’ – how Proskauer built a London high yield offering in 12 monthsSlaughters, Gibson Dunn lead on Daily Mail’s £500m Telegraph Media Group acquisitionCohen & Gresser follows McDermott in eyeing up external investmentRevolving doors: Simpson Thacher, Latham, Sidley lead New Year London moves‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryFive partners vie to succeed Hoyland as Simmons managing partner